The present invention relates to a method for stabilizing chimeric immunoglobulins or immunoglobulin fragments. Furthermore, the invention also provides a stabilized anti-EGP-2 scFv fragment.

The invention relates to imidazoquinolines of formula (I) for use in the treatment of protein kinase dependent diseases; pharmaceutical preparations comprising an imidazoquinoline, especially for the treatment of a protein kinase dependent disease; novel imidazoquinolines; and a process for the preparation of the novel imidazoquinolines.

Chemical patent from PubChem database. Patent Number: AT-E400291-T1. Title: Pharmaceutical Salt Forms. Filing Date: 2013-05-24. Inventors: Yamamoto, Hiroshi, Schmidt, Hans. Abstract: Novel pharmaceutical salt forms are provided, exhibiting improved physicochemical properties including enhanced solubility, stability, and bioavailabi... IPC Classifications: C08G, C08K, A61K. This patent covers 21 claims related to 4 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.

Chemical patent from PubChem database. Patent Number: AT-E401339-T1. Title: Novel Drug Delivery System. Filing Date: 2007-06-25. Inventors: Chen, Wei, Kumar, Raj, Williams, Sarah. Abstract: The present invention discloses a drug delivery system designed to provide targeted and sustained release of therapeutic agents, improving patient com... IPC Classifications: A61K, A61P, C07D. This patent covers 20 claims related to 3 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.

Chemical patent from PubChem database. Patent Number: AT-E401753-T1. Title: Novel Drug Delivery System. Filing Date: 1992-10-15. Inventors: Rodriguez, Juan, White, Jennifer. Abstract: The present invention discloses a drug delivery system designed to provide targeted and sustained release of therapeutic agents, improving patient com... IPC Classifications: C12N, C12P, A61K. This patent covers 12 claims related to 5 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.

Chemical patent from PubChem database. Patent Number: AT-E399781-T1. Title: Novel Chemical Entity. Filing Date: 2004-10-11. Inventors: Anderson, Robert, Davis, Linda. Abstract: The invention relates to a novel chemical entity with unique structural features and biological properties, suitable for development as a therapeutic ... IPC Classifications: C07D, C07F, A61K. This patent covers 19 claims related to 8 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.

Chemical patent from PubChem database. Patent Number: AT-E399781-T1. Title: Novel Chemical Entity. Filing Date: 2004-10-11. Inventors: Anderson, Robert, Davis, Linda. Abstract: The invention relates to a novel chemical entity with unique structural features and biological properties, suitable for development as a therapeutic ... IPC Classifications: C07D, C07F, A61K. This patent covers 19 claims related to 8 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.

A method of preparing a modified granulocyte colony stimulating factor (G-CSF) protein having reduced immunogenicity relative to human G-CSF comprises the steps of (i) identifying one or more potential T-cell epitopes within the amino acid sequence of human G-CSF (SEQ ID NO: 1 ); (ii) designing at least one sequence variant of at least one potential T-cell epitope identified in step (i), wherein the sequence variant eliminates or substantially reduces the MHC class II binding activity of the potential T-cell epitope; (iii) preparing, by recombinant DNA techniques, at least one modified G-CSF protein including a sequence variant designed in step (ii); (iv) evaluating at least one modified G-CSF protein prepared in step (iii) for G-CSF activity and immunogenicity; and (v) selecting a modified G-CSF protein evaluated in step (iv) that has substantially the same therapeutic G-CSF biological activity as, but substantially less immunogenicity than, human G-CSF.

Chemical patent from PubChem database. Patent Number: AT-E399521-T1. Title: Sustained Release Formulation. Filing Date: 2014-01-15. Inventors: Rodriguez, Juan, White, Jennifer. Abstract: A sustained release formulation is provided, designed to maintain therapeutic drug levels over extended periods, reducing dosing frequency and improvi... IPC Classifications: B01J, C07C, C07D. This patent covers 23 claims related to 8 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.

There is provided an antibody or antibody fragment which specifically binds to a portion of SEQ ID NO:2, wherein said portion consists of between 30 and 100 contiguous amino acids of SEQ ID NO:2, and wherein said portion contains amino acids selected from the group consisting of: (a) amino acid residues 54 to 59 of SEQ ID NO: 2; (b) amino acid residues 129 to 134 of SEQ ID NO: 2; (c) amino acid residues 53 to 58 of SEQ ID NO: 2; (d) amino acid residues 35 to 40 of SEQ ID NO: 2; (e) amino acid residues 33 to 38 of SEQ ID NO: 2; (f) amino acid residues 114 to 119 of SEQ ID NO: 2; (g) amino acid residues 101 to 105 of SEQ ID NO: 2; (h) amino acid residues 126 to 131 of SEQ ID NO: 2; (i) amino acid residues 113 to 118 of SEQ ID NO: 2; and (j) amino acid residues 158 to 162 of SEQ ID NO:2.